TAK-003, from the Japanese laboratory Takeda, is not likely to control the ongoing epidemic, according to the Pan American Health Organization . The organization emphasized the need to better understand the vaccine's effectiveness against different serotypes and its safety under real-world clinical conditions.
"The vaccines we currently have are not the best response to reduce transmission and prevent deaths," added Jarbas Barbosa, MD, PhD, PAHO's director. The fatality rate remains below 0.05%, but this figure could be hard to maintain if the situation becomes more uncontrolled. PAHO officials also highlighted the need to better characterize the vaccine's effectiveness and safety in the real world. They observed, for example, that when TAK-003 was investigated, the circulation of dengue serotype 3 was almost nonexistent, so the efficacy data against that serotype"are very limited."
Tropical Disease Dengue Dengue Fever Vaccine Vaccines Patient Safety Epidemic Immunizations Vaccination Adverse Effects Side Effects Artificial Intelligence Deep Learning AI NPL Machine Learning ML Natural Language Processing Artificial Neural Networks Bacteria Bacterial Infection Clinical Management Health Services Health Care Services Outbreak
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: ABC - 🏆 471. / 51 Read more »
Source: truthout - 🏆 69. / 68 Read more »
Source: NBCDFW - 🏆 288. / 63 Read more »
Source: NBCPhiladelphia - 🏆 569. / 51 Read more »
Source: WGAL - 🏆 331. / 59 Read more »
Source: cnnbrk - 🏆 393. / 55 Read more »